EUVIMEDEUVIMED entdecken
Crossref

Choosing Between Atezolizumab-Bevacizumab and STRIDE in First-Line Advanced Hepatocellular Carcinoma

Praloy Basu, Rajan Yadav, Goutham Sunny, Abinash Patnaik

International Journal of Science and Research (IJSR) · 24.05.2026 · 1243-1249

DOI: 10.21275/sr26520174441 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Science and Research (IJSR), erschienen am 24.05.2026. Verfasst von Praloy Basu und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Basu, P., Yadav, R., Sunny, G., & Patnaik, A. (2026). Choosing Between Atezolizumab-Bevacizumab and STRIDE in First-Line Advanced Hepatocellular Carcinoma. International Journal of Science and Research (IJSR), 1243-1249. https://doi.org/10.21275/sr26520174441

Vancouver

Basu P, Yadav R, Sunny G, Patnaik A. Choosing Between Atezolizumab-Bevacizumab and STRIDE in First-Line Advanced Hepatocellular Carcinoma. International Journal of Science and Research (IJSR). 2026:1243-1249. doi:10.21275/sr26520174441

BibTeX
@article{Basu2026,
  author = {Basu, Praloy and Yadav, Rajan and Sunny, Goutham and Patnaik, Abinash},
  title = {Choosing Between Atezolizumab-Bevacizumab and STRIDE in First-Line Advanced Hepatocellular Carcinoma},
  journal = {International Journal of Science and Research (IJSR)},
  year = {2026},
  pages = {1243--1249},
  doi = {10.21275/sr26520174441}
}
Kostenlos starten →